|Bid||2.7600 x 4000|
|Ask||3.0000 x 4000|
|Day's Range||2.7900 - 2.9450|
|52 Week Range||2.1500 - 6.3000|
|Beta (3Y Monthly)||2.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.
The Montgomery County biotech company says it wants to focus on the commercial development of its late-stage drug candidates targeting the human papillomavirus.
In 2009 J. Kim was appointed CEO of Inovio Pharmaceuticals, Inc. (NASDAQ:INO). This analysis aims first to contrast...
Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is a small-cap stock with a market capitalization of US$240m. While...
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The leader of George Mason University is set to become the next president of Georgia Tech. The Board of Regents of the University System of Georgia on Thursday named Ángel Cabrera as the sole finalist for the Georgia Tech presidency. Cabrera is currently president of George Mason University, a renowned research institution and the largest public university in Virginia.
CEO of Inovio Pharmaceuticals Inc (NASDAQ:INO) Jong Joseph Kim sold 2,129,553 shares of INO on 06/03/2019 at an average price of $2.36 a share.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 28) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Arrowhead ...
Inovio Pharmaceuticals Inc. shares fell in the extended session Tuesday after the drug developer said that one of its partners is scaling back on a research collaboration. Inovio shares fell 6.7% after hours, following a 3.7% decline to close at $3.14. In a filing with the Securities and Exchange Commission, Inovio said AstraZeneca PLC subsidiary MedImmune is discontinuing a research agreement with the company with the exception of a drug candidate known as "MEDI0457." The companies will continue evaluating the drug for use in cancers associated with human papillomavirus, or HPV, and Inovio will be eligible for milestone payments should the drug receive market approval.
Shares of Workday W seesawed in extended trading on Tuesday — jumping as much as 2% before falling more than 1% — after the software company reported better-than-expected first-quarter earnings. Inovio Pharmaceuticals INO stock plummeted as much as 11% after news broke that Astrazeneca, a pharmaceutical company, will discontinue its research collaborations with the biotech company. Refinitiv consensus estimates had projected earnings of 49 cents per share and net sales of $479.5 million.
QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.
More revenue, more cash, lower expenses, and a lot of pipeline activity were the major stories for the biotech in Q1.
Inovio (INO) delivered earnings and revenue surprises of -3.45% and -36.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Plymouth Meeting, Pennsylvania-based company said it had a loss of 30 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...